Related Experiment Video
Updated: Aug 7, 2026
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
[Gefitinib treatment for carcinomatous meningitis in non-small cell lung cancer]
K Chouahnia1, J-M Brechot, G Des-Guetz
1Service d'Oncologie Médicale, Hôpital Avicenne, Bobigny, France. kader.chouahnia@avc.ap-hop-paris.fr
Background:
Carcinomatous meningitis is a major complication in Non Small Cell Lung Cancer (NSCLC). Despite treatment with radiotherapy alone or in combination with intrathecal and systemic chemotherapy, its prognosis remains poor.
Observation:
We report a case of a female non-smoker with adenocarcinoma with bronchoalveolar features presenting with carcinomatous meningitis three years after the diagnosis of her primary tumour. Gefitinib treatment was proposed because of the persistence of meningitic symptoms despite cranial irradiation. Clinical response was observed within 3 weeks and lasted for 9 months.
Conclusion:
Gefitinib may be effective in treating carcinomatous meningitis complicating NSCLC and should be considered in this situation given the absence of effective alternatives.
